Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults
November 16, 2024
November 16, 2024
DALLAS, Texas, Nov. 16 [Category: Health Care] -- The American Heart Association issued the following news release:
Research Highlights:
In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status an . . .
Research Highlights:
In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status an . . .